First reported by ft.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
AstraZeneca loses £20bn in value after major heart drug trial setback
From the article
AstraZeneca suffered one of its biggest market setbacks in years after disappointing trial results for a key heart disease drug wiped more than £20 billion from the company’s stock market… The post AstraZeneca loses £20bn in value after major heart drug trial setback appeared first on London Business News
Continue reading on LondonlovesbusinessYou might also wanna read
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The Independent·5h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
ireland-live.ie·5h ago
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT·6h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·7h ago
Major drugmaker loses $27 billion in market value after failed trial
MarketWatch·6h ago
AstraZeneca shares slide 9% after heart treatment disappoints in trial
ft.com·8h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.